Mangalam Drugs Peer Comparison
NSE: MANGALAM | BSE: 532637
₹30.02
₹-0.28
(-0.92%)
As on 04-Sep-2026 15:52IST
Market cap
₹48 Cr
Revenue (TTM)
₹232 Cr
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Edit
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
48 | 33,908 | 29,353 | 28,517 | 25,923 |
Revenue (₹ Cr) |
232 | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
-38.24 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
-16.43 | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
-33.16 | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
-- | 82.90 | 101.84 | -- | 67.12 |
Price-To-Book |
0.50 | 6.74 | 21.87 | 3.56 | 15.02 |
Income Statement (₹ Cr)
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
232.44 | 3,564.00 | 1,935.80 | 9,205.28 | 1,461.80 |
|
Total Income
|
232.78 | 3,686.00 | 1,948.58 | 9,449.59 | 1,489.25 |
|
Total Expenditure
|
241.21 | 2,792.00 | 1,485.56 | 8,195.15 | 919.25 |
|
EBITDA
|
-8.77 | 772.00 | 450.24 | 1,010.13 | 542.56 |
|
Depreciation
|
17.45 | 226.00 | 50.83 | 857.51 | 37.68 |
|
EBIT
|
-26.22 | 546.00 | 399.41 | 152.62 | 504.88 |
|
Interest
|
15.84 | 217.00 | 40.84 | 342.73 | 3.77 |
|
Other Income
|
0.34 | 122.00 | 12.78 | 244.31 | 27.45 |
|
Exceptional Items
|
0.00 | 12.00 | 0.00 | -216.88 | 0.00 |
|
Profit before Tax
|
-41.72 | 463.00 | 371.35 | -162.68 | 528.56 |
|
Provision for Tax
|
-4.08 | 49.00 | 83.14 | 209.13 | 141.21 |
|
Profit after Tax
|
-37.64 | 414.00 | 288.22 | -371.81 | 387.35 |
Liabilities (₹ Cr)
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
103.32 | 4,940.00 | 1,288.82 | 8,162.62 | 1,653.56 |
|
Minority Interest
|
0.00 | -5.00 | 0.00 | 0.00 | -1.13 |
|
Non-Current Liabilities
|
15.33 | 1,712.00 | 202.03 | 5,044.14 | 42.40 |
|
Current Liabilities
|
189.49 | 1,622.00 | 835.87 | 4,758.28 | 230.82 |
|
Total Liabilities
|
-- | 8,100.00 | 1,451.43 | 15,513.53 | 1,549.26 |
Assets (₹ Cr)
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
141.86 | 5,343.00 | 519.60 | 10,211.52 | 1,026.85 |
|
Current Assets
|
155.69 | 2,606.00 | 1,681.81 | 7,191.66 | 881.27 |
|
Total Assets
|
-- | 8,100.00 | 1,451.43 | 15,513.53 | 1,549.26 |
|
Total Debt*
|
-- | 1,859.00 | 393.17 | 4,720.27 | 8.18 |
|
Net Current Assets
|
-33.80 | 984.00 | 845.94 | 2,433.38 | 650.46 |
|
Contingent Liabilities
|
-- | 770.26 | 12.25 | 99.76 | 15.38 |
Cashflow (₹ Cr)
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-- | -22.00 | 159.18 | 892.30 | 118.34 |
|
Cash Flow from Investing Activities
|
-- | -783.00 | -64.81 | -477.46 | -223.94 |
|
Cash from Financing Activities
|
-- | 409.00 | -39.81 | -440.83 | 261.12 |
|
Net Cash Inflow / Outflow
|
-- | -396.00 | 54.56 | -25.99 | 155.52 |
Ratios
Profitability Ratios
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-- | 4.07 | 26.97 | 6.61 | 20.14 |
|
ROE (%)
|
-32.62 | 8.38 | 29.77 | -3.85 | 25.18 |
|
ROA (%)
|
-11.28 | 4.94 | 24.77 | -2.21 | 21.93 |
|
EBIT Margin (%)
|
-11.28 | 15.32 | 20.63 | 1.66 | 34.54 |
|
Net Margin (%)
|
-16.17 | 11.23 | 14.79 | -3.93 | 26.01 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-22.17 | 18.37 | 46.65 | 0.78 | 40.90 |
|
EBIT Growth (%)
|
-549.97 | 252.26 | 62.13 | -70.53 | 124.50 |
|
Net Profit Growth (%)
|
-296.70 | 377.85 | 89.49 | -1,383.43 | 104.15 |
|
EPS Growth (%)
|
-296.70 | 1,001.33 | 78.60 | -484.84 | 42.32 |
|
Book Value Growth (%)
|
-- | 29.77 | 42.49 | 2.28 | 94.96 |
Valuation Ratios
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-1.28 | 85.09 | 100.28 | -91.14 | 67.12 |
|
Price / Book Value
|
0.50 | 6.74 | 21.87 | 3.56 | 15.02 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
|
EV/EBITDA
|
-15.25 | 45.82 | 65.00 | 32.33 | 47.41 |
|
Market Cap (₹ Cr)
|
-- | 23,064.69 | 0.00 | 29,731.27 | 19,988.69 |
Solvency Ratios
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.07 | 0.31 | 0.11 | 0.53 | 0.01 |
|
Short term debt to equity ratio
|
-- | 0.11 | 0.54 | 0.12 | 0.02 |
|
Current Ratio
|
0.82 | 1.61 | 2.01 | 1.51 | 3.82 |
|
Quick Ratio
|
0.28 | 1.06 | 1.14 | 0.87 | 2.82 |
|
Interest Coverage
|
-1.63 | 3.13 | 10.09 | 0.53 | 141.16 |
Operating Efficiency Ratios
| Mangalam Drugs | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.34 | 16.50 | 26.28 | 23.44 | 24.80 |
|
Asset Turnover
|
0.70 | 0.43 | 1.66 | 0.55 | 0.83 |
|
Receivable days
|
-- | 60.36 | 47.59 | 77.05 | 90.06 |
|
Inventory Days
|
-- | 64.42 | 62.58 | 77.13 | 61.02 |
|
Payable days
|
-- | 218.94 | 228.78 | 173.49 | 96.06 |
|
Cash Conversion Cycle
|
-- | -94.15 | -118.62 | -19.30 | 55.02 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
